Lilly crafts deal for up to 5 new ALS antibodies with UK biotech Alchemab

It’s been a rough month for several clinical amyotrophic lateral sclerosis (ALS) candidates, but that’s not stopping Eli Lilly from pursuing new drugs of its own for the devastating neurological disease. The Big Pharma has inked a deal with British biotech Alchemab Therapeutics to develop new antibodies for ALS.